GLP-1 and PCOS: separating real benefits from TikTok hype

What did @primalpcos actually say?

The creator claims that Ozempic "stimulates insulin release from the pancreas" and that insulin is "a fat storing hormone." They also claim it "decreases glucagon," which they call "a fat burning hormone." The framing implies these two mechanisms together make Ozempic problematic, or at least paradoxical, for people trying to lose weight. That's a specific mechanistic argument, and it deserves a specific mechanistic response.

To be fair, none of this is fabricated. These are real pharmacological actions of semaglutide. The question is whether the interpretation holds up when you look at the full picture of what those actions actually do in a living person.

Does the science back this up?

Partially, but the framing is misleading enough to matter. Yes, GLP-1 receptor agonists like semaglutide stimulate glucose-dependent insulin secretion. Yes, they suppress glucagon. Both of these are documented mechanisms, described in detail by Drucker (2018, New England Journal of Medicine) and confirmed across multiple phase 3 trials. So the creator is not making things up.

But here's where it gets complicated. The insulin release triggered by semaglutide is glucose-dependent, meaning it only happens when blood glucose is elevated. It is not a flat, sustained insulin spike. The glucagon suppression, meanwhile, helps prevent the liver from dumping glucose into the bloodstream between meals. Calling these effects simply "fat storing" and "not fat burning" strips out the context that makes them clinically meaningful. Wilding et al. (2021, NEJM) showed participants on semaglutide lost an average of 14.9% of body weight over 68 weeks. That does not happen if the drug is simply driving fat storage.

What did they get wrong (or right)?

They got the basic pharmacology right. Semaglutide does stimulate insulin and suppress glucagon. Credit where it's due.

What they got wrong is the interpretation. Labeling insulin as purely "a fat storing hormone" is a reductive framing that ignores insulin's role in glucose disposal and its behavior in a caloric deficit. Insulin is context-dependent. When you are eating less, as most people on semaglutide do because of its profound appetite-suppressing effects, insulin's anabolic signaling is blunted by low substrate availability. The body does not store fat it is not receiving.

The glucagon framing is similarly oversimplified. Glucagon promotes hepatic glucose output and lipolysis under fasting conditions. Suppressing it after a meal is appropriate physiology, not a metabolic sabotage. Jensen et al. (2021, Diabetes Care) noted that the glucagon suppression from GLP-1 agonists is primarily postprandial and is actually part of why these drugs improve glycemic control without causing significant hypoglycemia in most patients.

• Calling insulin a "fat storing hormone" without qualification is technically incomplete and contextually misleading.
• Glucagon suppression being framed as anti-fat-burning ignores when and why that suppression occurs.
• The net metabolic outcome of semaglutide, which is robust weight loss in controlled trials, contradicts the implied conclusion.

What should you actually know?

Semaglutide produces meaningful weight loss in the majority of people who use it, and that is not despite its insulin and glucagon effects, it is partly because of them. The glucose-dependent insulin release prevents hyperglycemia without causing rebound hunger-inducing hypoglycemia. The glucagon suppression keeps the liver from undermining the process. Together, these effects reduce caloric intake, improve blood sugar stability, and create an environment where the body draws on stored energy.

Reducing complex endocrine pharmacology to "insulin stores fat, glucagon burns fat, therefore Ozempic is contradictory" makes for a clean TikTok argument, but it is not how the physiology works in practice. If you have PCOS and are concerned about how GLP-1 agonists interact with insulin resistance, those are real and valid questions worth discussing with a clinician. But the mechanism described in this video does not support the implied concern that Ozempic is working against fat loss.

Nauck and Meier (2018, Diabetologia) provide a thorough review of GLP-1 receptor agonist mechanisms that is worth reading if you want the full picture rather than a simplified hormone narrative.

Bottom line: is this worth worrying about?

The specific mechanisms described are real. The conclusion being implied, that Ozempic's insulin and glucagon effects undermine weight loss, is not supported by the evidence. The clinical trial data showing significant weight reduction directly contradicts this framing. Understanding how hormones work in isolation is not the same as understanding what they do in the context of a drug that also dramatically reduces caloric intake and slows gastric emptying. Context matters, and this video leaves most of it out.